Inhibition of Aflatoxin B1 by Aqueous extract from Green Cardamom
DOI:
https://doi.org/10.54361/10.26719/LJM18-1.03Keywords:
mycotoxins, aflatoxins, inhibition, natural extracts, Aspergillus flavusAbstract
Aflatoxin B1 is a secondary metabolite produced by Aspergillus section Flavi during their development, is one of the most dangerous mycotoxins identified to date, that may contaminate many commodities, especially in tropical and sub-tropical regions. Aflatoxin B1 is believed to be the most essential member of this family of mycotoxins, due to its carcinogenic properties in humans and animals. However, there are many strategies to prevent mycotoxin contamination in which some of them are based on the use of natural compounds that may able to minimize the toxin synthesis pathways. Aims: The current work aimed to identify specific compounds from Green Cardamom that expected to interfere with aflatoxin production pathway. Methodology: The adapted method was based on the incubation of fungal culture with different concentrations of the aqueous extraction of Green Cardamom. Results: The aqueous extract of Green Cardamom was able to inhibit Fungal growth and Aflatoxin B1 production by the toxigenic strain of Aspergillus Flavus in a dose-dependent manner. Discussion: the reduction of Aflatoxin B1 production was significantly higher (94.34%) in comparison with other plant extracts such as Caffeine (50%), and reduced fungal growth with an average of (4%) compared to control. Conclusion: Aqueous Extracts of Green Cardamom show an obvious reduction in inhibition synthesis of Aflatoxin B1 by toxigenic Aspergillus strain, the adapted method was effective, but even further investigation is still recommended.
Downloads
References
Marasas, W.F.O.; Gelderblom, W.; Shephard, G.; Vismer, H. ‘Mycotoxins: A global problem. In Mycotoxins: detection methods, management, public health and agricultural trade, 2008, pp. 29–39. doi:10.1079/9781845930820.0029. ]
Taniwaki, M.H.; Pitt, J.I.; Magan, N. Aspergillus Species and Mycotoxins: Occurrence and Importance in Major Food Commodities. Curr. Opin. Food Sci. 2018, 23, 38–43. [CrossRef]
Amaike, S.; Keller, N.P. Aspergillus flavus . Annu. Rev. Phytopathol. 2011, 49, 107–133. [CrossRef]
Udomkun, P.; Wiredu, A.N.; Nagle, M.; Müller, J.; Vanlauwe, B.; Bandyopadhyay, R. Innovative Technologies to Manage Aflatoxins in Foods and Feeds and the Profitability of Application—A Review. Food Control 2017, 76, 127–138. [CrossRef] [PubMed]
IARC. Fungi Producing Significant Mycotoxins; IARC: Lyon, France, 2012; pp. 1–30.
Caceres, I.; Khoury, A.A.; El Khoury, R.; Lorber, S.; Oswald, I.P.; Khoury, A.E.; Atoui, A.; Puel, O.; Bailly, J.-D. Aflatoxin Biosynthesis and Genetic Regulation: A Review. Toxins 2020, 12, 150. [CrossRef] [PubMed]
Kemboi, D.C.; Ochieng, P.E.; Antonissen, G.; Croubels, S.; Scippo, M.-L.; Okoth, S.; Kangethe, E.K.; Faas, J.; Doupovec, B.; Lindahl, J.F.; et al. Multi-Mycotoxin Occurrence in Dairy Cattle and Poultry Feeds and Feed Ingredients from Machakos Town, Kenya. Toxins 2020, 12, 762. [CrossRef]
Elhadi Emh. Mohammad Gunbeaj1, Syed Amir Ashraf2, Nada Basher El-Akary1, Subuhi Sherwani3, Amir Mahgoub Awadelkareem2, Wahid Ali Khan4 and Mohd Wajid Ali Khan. Effect of Storage on the Level of Aflatoxin M1 in Milk and Other Dairy Products Sold at Tripoli Province, Libya. J Pure Appl Microbiol, 12(4), 1959-1964 Dec. 2018
Meissonnier, G.M.; Pinton, P.; Laffitte, J.; Cossalter, A.-M.; Gong, Y.Y.;Wild, C.P.; Bertin, G.; Galtier, P.; Oswald, I.P. Immunotoxicity of Aflatoxin B1: Impairment of the Cell-Mediated Response to Vaccine Antigen and Modulation of Cytokine Expression. Toxicol. Appl. Pharmacol. 2008, 231, 142–149. [CrossRef]
Ismail, A.; Gonçalves, B.L.; de Neeff, D.V.; Ponzilacqua, B.; Coppa, C.F.S.C.; Hintzsche, H.; Sajid, M.; Cruz, A.G.; Corassin, C.H.; Oliveira, C.A.F. Aflatoxin in Foodstuffs: Occurrence and Recent Advances in Decontamination. Food Res. Int. 2018, 113, 74–85. [CrossRef]
Groopman, J.D.; Kensler, T.W.;Wild, C.P. Protective Interventions to Prevent Aflatoxin-Induced Carcinogenesis in Developing Countries. Annu. Rev. Public Health 2008, 29, 187–203. [CrossRef]
Sarma, U.P.; Bhetaria, P.J.; Devi, P.; Varma, A. Aflatoxins: Implications on Health. Indian J. Clin. Biochem. 2017, 32, 124–133. [CrossRef]
Bailly, S.; Mahgubi, A.; Carvajal-Campos, A.; Lorber, S.; Puel, O.; Oswald, I.; Bailly, J.-D.; Orlando, B. Occurrence and Identification of Aspergillus Section Flavi in the Context of the Emergence of Aflatoxins in French Maize. Toxins 2018, 10, 525. [CrossRef]
Moretti, A.; Pascale, M.; Logrieco, A.F. Mycotoxin Risks under a Climate Change Scenario in Europe. Trends Food Sci. Technol. 2019, 84, 38–40. [CrossRef]
Pankaj, S.K.; Shi, H.; Keener, K.M. A Review of Novel Physical and Chemical Decontamination Technologies for Aflatoxin in Food. Trends Food Sci. Technol. 2018, 71, 73–83. [CrossRef]
Rodrigues, I.; Naehrer, K. A Three-Year Survey on the Worldwide Occurrence of Mycotoxins in Feedstuffs and Feed. Toxins 2012, 4, 663–675. [CrossRef]
Luo, Y.; Liu, X.; Li, J. Updating Techniques on Controlling Mycotoxins—A Review. Food Control 2018, 89, 123–132. [CrossRef]
18. Moral, J.; Garcia-Lopez, M.T.; Camiletti, B.X.; Jaime, R.; Michailides, T.J.; Bandyopadhyay, R.; Ortega-Beltran, A. Present Status and Perspective on the Future Use of Aflatoxin Biocontrol Products. Agronomy 2020, 10, 491. [CrossRef]
Onaran, A.; Yanar, Y. In Vivo and In Vitro Antifungal Activities of Five Plant Extracts Against Various Plant Pathogens. Egypt. J. Biol. Pest Control 2016, 26, 405–411.
El Khoury, R.; Caceres, I.; Puel, O.; Bailly, S.; Atoui, A.; Oswald, I.P.; El Khoury, A.; Bailly, J.-D. Identification of the Anti-Aflatoxinogenic Activity of Micromeria Graeca and Elucidation of Its Molecular Mechanism in Aspergillus flavus. Toxins 2017, 9, 87. [CrossRef]
Thippeswamy, S.; Mohana, D.; Umesh, A.; Kiragandur, M. Inhibitory Activity of Plant Extracts on Aflatoxin B1 Biosynthesis by Aspergillus Flavus. J. Agric. Sci. Technol. 2014, 16, 1123–1132.
Loi, M.; Paciolla, C.; Logrieco, A.F.; Mulè, G. Plant Bioactive Compounds in Pre- and Postharvest Management for Aflatoxins Reduction. Front. Microbiol. 2020, 11, 243. [CrossRef]
Mithöfer, A.; Maffei, M. General Mechanisms of Plant Defense and Plant Toxins. In Plant Toxins; Springer: Berlin/Heidelberg, Germany, 2017; ISBN 978-94-007-6463-7.
Pisoschi, A.M.; Pop, A.; Cimpeanu, C.; Predoi, G. Antioxidant Capacity Determination in Plants and Plant-Derived Products: A Review. Oxid. Med. Cell. Longev. 2016, 2016, 9130976. [CrossRef]
Camargo-Ricalde, S.L. (2000). Descripción, distribución, anatomía, composición química y usos de Mimosa tenuiflora (Fabaceae-Mimosoideae) en México. Revista De Biologia Tropical, 48, 939-954. .
de Souza, R.S.O.; de Albuquerque, U.P.; Monteiro, J.M.; de Amorim, E.L.C. Jurema-Preta (Mimosa Tenuiflora [Willd.] Poir.): A Review of Its Traditional Use, Phytochemistry and Pharmacology. Braz. Arch. Biol. Technol. 2008, 51, 937–947. [CrossRef]
Lozoya, X.; Navarro, V.; Arnason, J.T.; Kourany, E. Experimental Evaluation of Mimosa Tenuiflora (Willd.) Poir. (Tepescohuite) I. Screening of the Antimicrobial Properties of Bark Extracts. Archivos de investigacion medica. 1989, 20, 87–93.
Rivera-Arce, E.; Chávez-Soto, M.A.; Herrera-Arellano, A.; Arzate, S.; Agüero, J.; Feria-Romero, I.A.; Cruz-Guzmán, A.; Lozoya, X. Therapeutic Effectiveness of a Mimosa Tenuiflora Cortex Extract in Venous Leg Ulceration Treatment. J. Ethnopharmacol. 2007, 109, 523–528. [CrossRef]
Shrivastava, R. Clinical Evidence to Demonstrate That Simultaneous Growth of Epithelial and Fibroblast Cells Is Essential for Deep Wound Healing. Diabetes Res. Clin Pract. 2011, 92, 92–99. [CrossRef]
Padilha, I.Q.M.; Pereira, A.V.; Rodrigues, O.G.; Siqueira-Júnior, J.P.; do Socorro, V. Pereira, M. Antimicrobial Activity of Mimosa Tenuiflora (Willd.) Poir. from Northeast Brazil against Clinical Isolates of Staphylococcus Aureus. Rev. Bras. Farmacogn. 2010, 20, 45–47. [CrossRef]
Martel-Estrada, S.A.; Olivas-Armendáriz, I.; Santos-Rodríguez, E.; Martínez-Pérez, C.A.; García-Casillas, P.E.; Hernández-Paz, J.; Rodríguez-González, C.A.; Chapa-González, C. Evaluation of in Vitro Bioactivity of Chitosan/Mimosa Tenuiflora Composites. Mater. Lett. 2014, 119, 146–149. [CrossRef]
Cruz, M.P.; Andrade, C.M.F.; Silva, K.O.; de Souza, E.P.; Yatsuda, R.; Marques, L.M.; David, J.P.; David, J.M.; Napimoga, M.H.; Clemente-Napimoga, J.T. Antinoceptive and Anti-Inflammatory Activities of the Ethanolic Extract, Fractions and Flavones Isolated from Mimosa Tenuiflora (Willd.) Poir (Leguminosae). PLoS ONE 2016, 11, e0150839. [CrossRef]
Vepsäläinen, J.; Auriola, S.; Tukiainen, M.; Ropponen, N.; Callaway, J. Isolation and Characterization of Yuremamine, a New Phytoindole. Planta Med. 2005, 71, 1053–1057. [CrossRef]
El Mahgubi, A.; Puel, O.; Bailly, S.; Tadrist, S.; Querin, A.; Ouadia, A.; Oswald, I.P.; Bailly, J.D. Distribution and Toxigenicity of Aspergillus Section Flavi in Spices Marketed in Morocco. Food Control 2013, 32, 143–148. [CrossRef]
Buchanan RL, Hoover DG, Jones SB (1983) Caffeine inhibition of aflatoxin production—mode of action. Appl Environ Microbiol 46:1193–1200
Marchese, S., Polo, A., Ariano, A., Velotto, S., Costantini, S., & Severino, L. (2018). Aflatoxin B1 and M1: Biological Properties and Their Involvement in Cancer Development. Toxins, 10(6), 214. https://doi.org/10.3390/toxins10060214
Narkwa, P.W., Blackbourn, D.J. and Mutocheluh, M. (2017) ‘Aflatoxin B1 inhibits the type 1 interferon response pathway via STAT1 suggesting another mechanism of hepatocellular carcinoma’, Infectious Agents and Cancer, 12(1). https://doi.org/10.1186/s13027-017-0127-8.
Daou, R., Claude Assaf, J., & El Khoury, A. (2022). Aflatoxins in the Era of Climate Change: The Mediterranean Experience. IntechOpen. doi: 10.5772/intechopen.108534
Kamalaveni S. (2019). A study on cardamom production and exports: Queen of spices. Int J Appl Res;5(10):225-228.
Braicu C, Puia C, Bodoki E, Socaciu C. Screening and quantification of aflatoxins and ochratoxin a in different cereals cultivated in Romania using thin‐layer chromatography‐densitometry. Journal of Food Quality. 2008 Feb;31(1):108-20.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Anwar Elmahgubi, salem Masoud Khalifa, Mahmoud Bashir Agena, Ahlam Althabet, Alsouri Ahmed Alsouri (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
